Eptastigmine: Ten years of pharmacology, toxicology, pharmacokinetic, and clinical studies

CNS Drug Reviews

Volumn 7, Issue 4, 2001, Pages 369-386

  Braida, Daniela ^a   Sala, Mariaelvina ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Acetylcholine; Alzheimer's disease; Cholinesterase inhibitors; Cognition; Eptastigmine

Indexed keywords

DONEPEZIL; HEPTYLSTIGMINE TARTRATE; PHYSOSTIGMINE DERIVATIVE; SCOPOLAMINE; TACRINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; BRAIN BLOOD FLOW; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG DISTRIBUTION; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; GRANULOCYTOPENIA; HUMAN; MAJOR CLINICAL STUDY; MEMORY; NONHUMAN; PHARMACODYNAMICS; RANDOMIZED CONTROLLED TRIAL; RAT; REVIEW; SIDE EFFECT;

EID: 0035726687     PISSN: 1080563X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3458.2001.tb00205.x     Document Type: Review

References (70)

1. 3H]methylcarbamylcholine in rat brain
2. Pharmacodynamics and pharmacokinetics of eptastigmine in elderly subjects
3. The second generation of cholinesterase inhibitors: Clinical and pharmacological effects
4. Effect of food of the absorption of eptastigmine
5. Eptastigmine: A view point
6. Eptastigmine improves eight arm radial maze performance in aged rats
7. Eptastigmine restores the aged rat's normal cortical spectral power pattern
8. An inverted U-shaped curve for heptylphysostigmine on radial maze performance in rats: Comparison with other cholinesterase inhibitors
9. Cannabinoid-induced working memory impairment is reversed by a second cholinesterase inhibitor in rats
10. Excitatory and inhibitory effects of second-generation cholinesterase inhibitor on rat gastrointestinal transit
11. A long-lasting cholinesterase inhibitor affecting neural and behavioral processes
12. Anticholinesterase activity of a new carbamate, heptylphysostigmine, in view of its use in patients with Alzheimer-type dementia
13. 2 adrenoceptor antagonists potentiate acetylcholinesterase inhibitor effects on passive avoidance learning in the rat
14. A double-blind, placebo-controlled, clinical trial in Alzheimer disease patients
15. Relationship between pharmacodynamic activity and cognitive effects of eptastigmine in patients with Alzheimer's disease
16. Effect of acute and short-term administration of cholinomimetic drugs on corticosterone secretion in the rat
17. A rapid potentiometric determination of cholinesterase in plasma and red cells: Application to eptastigmine monitoring
18. Eptastigmine augments basal and GHRH-stimulated growth hormone release in young and old dogs
19. Coadministration of cholinesterase inhibitors and idazoxan: Effects of neurotransmitters in rat cortex in vivo
20. Cholinesterase inhibitor effects on neurotransmitters in rat cortex in vivo
21. Target population in phase-I clinical-trials of cholinergic compounds in Alzheimer's disease. The role of the bridging study
22. The behavioral effects of heptyl physostigmine, a new cholinesterase inhibitor, in tests of long-term and working memory in rodents
23. The effects of novel cholinesterase inhibitors and selective muscarinic receptor agonists in tests of reference and working memory
24. The effect of heptylphysostigmine, a new cholinesterase inhibitor, on the central cholinergic system of the rat
25. Controlled trial of tacrine in Alzheimer's disease
26. Effect of the subchronic treatment with the acetylcholinesterase inhibitor heptastigmine on central cholinergic transmission and memory impairment in aged rats
27. From molecular structure to Alzheimer therapy
28. Cholinesterase inhibitors for Alzheimer's disease therapy: From tacrine to future applications
29. Cholinergic foundation of Alzheimer's disease therapy
30. Power spectral analysis of heart rate variability in Alzheimer's disease patients treated with cholinesterase inhibitor
31. The long-acting cholinesterase inhibitor heptylphysostigmine attenuates the scopolamine-induced learning impairment of rats in a 14-unit T-maze
32. Eptastigmine: A cholinergic approach to the treatment of Alzheimer's disease
33. Relationship between pharmacokinetics and pharmacodynamics of eptastigmine in young healthy volunteers
34. A 25-week placebo-controlled study of eptastigmine in patients with Alzheimer disease
35. Efficacy and safety of eptastigmine for the treatment of patients with Alzheimer's disease
36. A 6-month, double-blind, placebo-controlled trial of eptastigmine in Alzheimer's disease
37. Two-year treatment of Alzheimer's disease with eptastigmine
38. Approaches to cholinergic therapy in Alzheimer's disease
39. A double-blind, placebo-controlled study of the effects of eptastigmine on scopolamine-induced cognitive deficits in healthy male-subjects
40. Heptyl-physostigmine enhances basal forebrain control of cortical cerebral blood flow
41. Effects of cholinesterase inhibitors on a two-component chained schedule performance
42. Maximum tolerated dose and pharmacodynamics of eptastigmine in elderly healthy volunteers
43. Drug therapy: Treatment of Alzheimer's disease
44. Eptastigmine
45. Cholinesterase inhibitors increase secretion of APPs in rat brain cortex
46. Transdermal delivery of cholinesterase-inhibitors. Rationale and therapeutic potential
47. Inhibition of human brain and RBC acetylcholinesterase (AChE) by heptylphysostigmine (HPTL)
48. A patient-side technique for real-time measurement of acetylcholinesterase activity during monitoring of eptastigmine treatment
49. Cholinesterase inhibitors in the treatment of Alzheimer's disease: A comparison of tolerability and pharmacology
50. Preferential inhibition of acetylcholinesterase molecular forms in rat brain
51. Differential inhibition of acetylcholinesterase molecular forms in normal and Alzheimer disease brain
52. Effects of eptastigmine, a new cholinesterase inhibitor, on regional cerebral blood flow in Alzheimer patients
53. Profile of cholinomimetic drugs in primates-status of screens for potential Alzheimer therapies
54. Reversal of cognitive impairment by heptyl-physostigmine, a long-lasting cholinesterase inhibitor, in primates
55. Prolonged effects of cholinesterase inhibition with eptastigmine on the cerebral blood flow-metabolism ratio of normal rats
56. Cholinesterase inhibition improves blood flow in the ischemic cerebral cortex
57. Pharmacokinetics of heptastigmine in rats
58. A multiple-dose safety trial of eptastigmine in Alzheimer's desease, with pharmacodynamic observations of red blood cell cholinesterase
59. Effects of cholinergic drugs on neocortical EEG and flash visual evoked potentials in the mouse
60. Eptastigmine-phosphotriesterase combination in DFP intoxication
61. Protection of mice against soman by pretreatment with eptastigmine and physostigmine
62. Phosphotriesterase pralidoxime-2-chloride (2-PAM) and eptastigmine treatments and their combinations in DFP intoxication
63. Success of pyridoxstigmine, physostigmine, eptastigmine and phosphotriesterase treatments in acute sarin intoxication
64. Determination of heptylphysostigmine by high-performance liquid chromatography with electrochemical detection
65. Kinetics of cholinesterase inhibition by eptastigmine in man
66. The behavioral effects of heptylphysostigmine on rats lesioned in the nucleus accumbens
67. Cholinergic modulation of a decrement in social investigation following repeated contacts between mice
68. Determination of heptylphysostigmine in plasma by high-performance liquid chromatography with electrochemical detection
69. Effects of MF268, a new cholinesterase inhibitor, on acetylcholine and biogenic amines in rat cortex